Category: News

DNAstack today announced the launch of Clinical Evidence Beacons on the Beacon Network, a real-time search engine for finding genetic mutations across a global network of genomic datasets.These additions will enable medical laboratories to crowdsource the interpretation of variants through a secure social network.Accurately interpreting DNA variants identified through genetic testing is essential for patients […]

DNAstack today announced its participation in a new project to accelerate the development of a national software platform for precision health in Canada.

DNAstack, a cloud genomics company, today is announcing a partnership with Sentieon, an award-winning bioinformatics software company. 

We fundamentally believe that democratization of genomics information through sharing will massively accelerate discoveries that will lead to better treatments and outcomes for patients affected by genetic diseases. 

We can avoid long diagnostic odyssies by connecting patients’ data into networks that leverage — in realtime — large and exponentially growing volumes of information. This is the inspiration behind our work on the Beacon Project for the Global Alliance for Genomics & Health, where we are defining industry standards for sharing genomic variants.

Today, DNAstack announced the launch of a major update to its cloud-based genomics software platform. 

The update contains many new features, including a revolutionary application called Workflows that makes it easier and more affordable than ever for genome scientists to find, develop, share, and run bioinformatics workflows at scale. The app brings the most advanced technologies and standards for bioinformatics to market and positions DNAstack as a commercial leader in cloud genomics.

Almost sixty percent of the human population resides in Asia and Africa, but only a fraction of the world’s human genomic sequencing efforts cover that community.

JLABS will let startups in therapeutic, pharmaceutical, medical device and consumer health research test out ideas with access to state-of-the-art equipment, without giving up equity.